Meta-analysis: Antibiotic therapy for small intestinal bacterial overgrowth

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 8, 2013, Pages 925-934

  Shah, S C ^a   Day, L W ^a,b   Somsouk, M ^b   Sewell, J L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORTETRACYCLINE; CIPROFLOXACIN; GUAR GUM; METRONIDAZOLE; NEOMYCIN; PLACEBO; RIFAXIMIN;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ARTICLE; BREATH ANALYSIS; CELIAC DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; INTESTINE INFECTION; IRRITABLE COLON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL INTESTINAL BACTERIAL OVERGROWTH; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BREATH TESTS; HUMANS; INTESTINE, SMALL; RIFAMYCINS;

EID: 84884905656     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12479     Document Type: Article

References (35)

1. Lappinga PJ, Abraham SC, Murray JA, Vetter EA, Patel R, Wu TT,. Small intestinal bacterial overgrowth: histopathologic features and clinical correlates in an underrecognized entity. Arch Pathol Lab Med 2010; 134: 264-70.
2. Bures J, Cyrany J, Kohoutova D, et al,. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010; 16: 2978-90.
3. Dukowicz AC, Lacy BE, Levine GM,. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol 2007; 3: 112-22.
4. Teo M, Chung S, Chitti L, et al,. Small bowel bacterial overgrowth is a common cause of chronic diarrhea. J Gastroenterol Hepatol 2004; 19: 904-9.
5. Gasbarrini A, Corazza GR, Gasbarrini G, et al,. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 2009; 29 (Suppl. 1): 1-49.
6. Pimentel M, Chow EJ, Lin HC,. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-9.
7. Su J, Smith MB, Rerknimitr R, Morrow D,. Small intestine bacterial overgrowth presenting as protein-losing enteropathy. Dig Dis Sci 1998; 43: 679-81.
8. Kerlin P, Wong L,. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 1988; 95: 982-8.
9. Corazza GR, Menozzi MG, Strocchi A, et al,. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 1990; 98: 302-9.
10. Singh VV, Toskes PP,. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Gastroenterol Rep 2003; 5: 365-72.
11. Van Citters GW, Lin HC,. Management of small intestinal bacterial overgrowth. Curr Gastroenterol Rep 2005; 7: 317-20.
12. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Available at: www.cochrane-handbook.org. Accessed August 27, 2013.
13. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
14. Collins BS, Lin HC,. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr 2011; 52: 382-6.
15. Furnari M, Parodi A, Gemignani L, et al,. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2010; 32: 1000-6.
16. Lauritano EC, Gabrielli M, Scarpellini E, et al,. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; 13: 111-6.
17. Lauritano EC, Gabrielli M, Lupascu A, et al,. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 22: 31-5.
18. Scarpellini E, Gabrielli M, Lauritano CE, et al,. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007; 25: 781-6.
19. Castiglione F, Rispo A, Di Girolamo E, et al,. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1107-12.
20. Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F,. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-glucose breath test. Curr Med Res Opin 2000; 16: 14-20.
21. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR,. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 551-6.
22. Chang MS, Minaya MT, Cheng J, Connor BA, Lewis SK, Green PH,. Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. Dig Dis Sci 2011; 56: 2939-46.
23. Lauritano EC, Gabrielli M, Scarpellini E, et al,. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008; 103: 2031-5.
24. Tuohy KM, Kolida S, Lustenberger AM, Gibson GR,. The prebiotic effects of biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides-a human volunteer study. Br J Nutr 2001; 86: 341-8.
25. Quigley EMM, Quera R,. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006; 130: S78-90.
26. Spiller R,. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 385-96.
27. Guglielmetti S, Mora D, Gschwender M, Popp K,. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 1123-32.
28. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R,. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387-94.
29. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, et al,. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008; 27: 48-57.
30. Pillai A, Nelson R,. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; 1: CD004611.
31. Dughera L, Elia C, Navino M, Cisaro F,; ARMONIA Study Group. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed 2007; 78: 111-6.
32. Stotzer PO, Blomberg L, Conway PL, Henriksson A, Abrahamsson H,. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD. Scand J Infect Dis 1996; 28: 615-9.
33. Shah ED, Basseri RJ, Chong K, Pimentel M,. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci 2010; 55: 2441-9.
34. Ford AC, Spiegel BM, Talley NJ, Moayyedi P,. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 1279-86.
35. Pimentel M, Lembo A, Chey WD, et al,. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.